| This is the talk page for discussing improvements to the Idarucizumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Idarucizumab.
|
Wiki Education assignment: PHMD 2040 Service - Learning Fall 2023 edit
This article was the subject of a Wiki Education Foundation-supported course assignment, between 31 May 2023 and 29 December 2023. Further details are available on the course page. Student editor(s): Balugaa3 (article contribs).
— Assignment last updated by Balugaa3 (talk) 21:23, 30 April 2024 (UTC)
New Sections edit
I will be adding information for 3 new sections: mechanism of action, medical uses and adverse effects. The sources I'm using are DailyMed, 2 systematic reviews by van der Horst et. al and Thibault et. al, and clinical guidelines from Canada and the US. --Balugaa3 (talk) 05:29, 1 May 2024 (UTC)
- Also, a new section called “Pharmacokinetics” should be added as there is evidence showing that marked decrease in renal function may decrease the effectiveness of idarucizumab. Dabigatran isn’t usually prescribed to those with low eGFR or severe CKD, but these findings are still relevant to patients on dabigatran who experience a sudden decline in renal function, like an acute kidney injury. The paper “Incomplete responses to the recommended dose of idarucizumab: a systematic review and pharmacokinetic analysis” by Athavale et. al (PMID: 32267185) illustrates this. Balugaa3 (talk) 20:13, 1 May 2024 (UTC)